Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Jiménez Díez-Canseco L, Gómez-Garcés JL, Zaragoza O.

Antimicrob Agents Chemother. 2012 Jun;56(6):3417-9. doi: 10.1128/AAC.06100-11. Epub 2012 Mar 5.

2.

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.

Singh-Babak SD, Babak T, Diezmann S, Hill JA, Xie JL, Chen YL, Poutanen SM, Rennie RP, Heitman J, Cowen LE.

PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.

3.

Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Bizerra FC, Jimenez-Ortigosa C, Souza AC, Breda GL, Queiroz-Telles F, Perlin DS, Colombo AL.

Antimicrob Agents Chemother. 2014;58(4):2438-40. doi: 10.1128/AAC.02189-13. Epub 2014 Jan 27.

4.

The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.

5.

Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.

Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA, Lockhart SR.

Antimicrob Agents Chemother. 2014 Aug;58(8):4690-6. doi: 10.1128/AAC.03255-14. Epub 2014 Jun 2.

6.

FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.

Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR.

Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10. Epub 2010 Sep 13.

7.

Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH.

Antimicrob Agents Chemother. 2013 Sep;57(9):4559-61. doi: 10.1128/AAC.01144-13. Epub 2013 Jul 1.

8.

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA.

Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13. Erratum in: Clin Infect Dis. 2014 Mar;58(5):754.

9.

Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.

Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW.

Antimicrob Agents Chemother. 2015 Sep;59(9):5405-12. doi: 10.1128/AAC.00624-15. Epub 2015 Jun 22.

10.

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN.

J Clin Microbiol. 2012 Apr;50(4):1199-203. doi: 10.1128/JCM.06112-11. Epub 2012 Jan 25.

11.

FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.

Costa-de-Oliveira S, Marcos Miranda I, Silva RM, Pinto E Silva A, Rocha R, Amorim A, Gonçalves Rodrigues A, Pina-Vaz C.

Antimicrob Agents Chemother. 2011 Mar;55(3):1312-4. doi: 10.1128/AAC.00589-10. Epub 2010 Dec 13.

12.

Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.

Saraya T, Tanabe K, Araki K, Yonetani S, Makino H, Watanabe T, Tsujimoto N, Takata S, Kurai D, Ishii H, Miyazaki Y, Takizawa H, Goto H.

J Clin Microbiol. 2014 Jul;52(7):2709-12. doi: 10.1128/JCM.03593-13. Epub 2014 Apr 30.

13.

FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW.

Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30.

14.

Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.

Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD.

Antimicrob Agents Chemother. 2012 Dec;56(12):6304-9. doi: 10.1128/AAC.00813-12. Epub 2012 Oct 1.

15.

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS.

Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.

16.

Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.

17.

Candidemia surveillance in Iowa: emergence of echinocandin resistance.

Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D.

Diagn Microbiol Infect Dis. 2014 Jun;79(2):205-8. doi: 10.1016/j.diagmicrobio.2014.02.016. Epub 2014 Mar 1.

PMID:
24666704
18.

Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.

Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, Uzunov M, Nguyen S, Leblond V, Mazier D, Datry A.

Antimicrob Agents Chemother. 2013 May;57(5):2380-2. doi: 10.1128/AAC.02037-12. Epub 2013 Feb 25.

19.

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS.

Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22.

20.

Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.

Lackner M, Tscherner M, Schaller M, Kuchler K, Mair C, Sartori B, Istel F, Arendrup MC, Lass-Flörl C.

Antimicrob Agents Chemother. 2014 Jul;58(7):3626-35. doi: 10.1128/AAC.00123-14. Epub 2014 Apr 14.

Items per page

Supplemental Content

Write to the Help Desk